Clearside Biomedical, Inc. financial data

Symbol
CLSD on Nasdaq
Industry
Pharmaceutical Preparations
Location
900 North Point Parkway, Suite 200, Alpharetta, GA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 500 % -31.2%
Debt-to-equity -236 % +93.9%
Return On Equity 127 % -96.2%
Return On Assets -92.9 % -5.56%
Operating Margin -320 % +76.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 75.8M shares +21.5%
Common Stock, Shares, Outstanding 74.7M shares +20.3%
Entity Public Float 64M USD -20%
Common Stock, Value, Issued 75K USD +21%
Weighted Average Number of Shares Outstanding, Basic 74.7M shares +20.6%
Weighted Average Number of Shares Outstanding, Diluted 74.7M shares +20.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 7.7M USD +248%
Research and Development Expense 20.7M USD +5.62%
General and Administrative Expense 11.7M USD -3.3%
Operating Income (Loss) -24.6M USD +17.8%
Net Income (Loss) Attributable to Parent -31.9M USD +14.6%
Earnings Per Share, Basic -0.45 USD/shares +26.2%
Earnings Per Share, Diluted -0.45 USD/shares +26.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 13.9M USD -51.8%
Cash, Cash Equivalents, and Short-term Investments 23.6M USD
Accounts Receivable, after Allowance for Credit Loss, Current 788K USD -10.7%
Other Assets, Current 13K USD -7.14%
Assets, Current 25.1M USD -18.5%
Property, Plant and Equipment, Net 3.35M USD +26.8%
Operating Lease, Right-of-Use Asset 667K USD -28.5%
Other Assets, Noncurrent 30K USD 0%
Assets 29.2M USD -15.3%
Accounts Payable, Current 2.36M USD +26.5%
Employee-related Liabilities, Current 1.47M USD +12.6%
Accrued Liabilities, Current 2.86M USD -20.7%
Liabilities, Current 5.59M USD -4.15%
Operating Lease, Liability, Noncurrent 412K USD -43.1%
Other Liabilities, Noncurrent 480K USD
Liabilities 64M USD +35.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 5K USD
Retained Earnings (Accumulated Deficit) -348M USD -10.1%
Stockholders' Equity Attributable to Parent -34.8M USD -171%
Liabilities and Equity 29.2M USD -15.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.85M USD -8.8%
Net Cash Provided by (Used in) Financing Activities 14.3M USD +4220%
Net Cash Provided by (Used in) Investing Activities -57K USD +50.4%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 74.7M shares +20.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6.44M USD
Deferred Tax Assets, Valuation Allowance 84M USD +14%
Operating Lease, Liability 1.01M USD -21.2%
Depreciation 28K USD +86.7%
Payments to Acquire Property, Plant, and Equipment 57K USD -50.4%
Property, Plant and Equipment, Gross 4.42M USD +24.7%
Operating Lease, Liability, Current 373K USD +3.04%
Deferred Tax Assets, Operating Loss Carryforwards 52.7M USD +4.76%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 7.52M USD 0%
Operating Lease, Payments 99K USD +4.21%
Additional Paid in Capital 313M USD +3.27%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%